Trial Profile
Phase II Study of Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer or Those With Progression on First Line Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Neuroendocrine tumours; Small cell lung cancer
- Focus Therapeutic Use
- 12 Jul 2023 Primary endpoint has been changed to overall Response Rate, Patients will be evaluated every 2 cycles until progression or off treatment (up to 3 years).
- 04 Jun 2021 Planned End Date changed from 1 Apr 2024 to 1 May 2025.
- 04 Jun 2021 Planned primary completion date changed from 1 Apr 2023 to 1 May 2025.